Challenging measles case definition: three measles outbreaks in three Health Regions of Portugal, February to April 2018

Gonçalo Figueiredo Augusto¹, Diogo Cruz¹, Andreia Silva¹, Natália Pereira¹, Bárbara Aguiar¹, Ana Leça¹, Elisabete Serrada¹, Paula Valente¹, Teresa Fernandes¹, Fernando Guerra¹, Paula Palminha², Elsa Vinagre³, Silvia Lopo³, Rita Cordeiro³, Emma Sáez-López³, Maria Neto⁴, Paulo Jorge Nogueira⁴, Graça Freitas⁴
¹. Directorate-General of Health, Lisbon, Portugal
². National Institute of Health Dr Ricardo Jorge, Lisbon, Portugal
³. European Public Health Microbiology Training (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
⁴. North Region Health Administration (SNS), Porto, Portugal

Correspondence: Paulo Nogueira (paulo.nogueira@dgs.min-saude.pt)

Citation style for this article:
Augusto Gonçalo Figueiredo, Cruz Diogo, Silva Andreia, Pereira Natália, Aguiar Bárbara, Leça Ana, Serrada Elisabete, Valente Paula, Fernandes Teresa, Guerra Fernando, Palminha Paula, Vinagre Elsa, Lopo Silvia, Cordeiro Rita, Sáez-López Emma, Neto Maria, Nogueira Paulo Jorge, Freitas Graça. Challenging measles case definition: three measles outbreaks in three Health Regions of Portugal, February to April 2018. Euro Surveill. 2018;23(28):pii=1800328. https://doi.org/10.2807/1560-7917.ES.2018.23.28.1800328

We report three simultaneous measles outbreaks with 112 confirmed cases in three Health Regions of Portugal, from February to April 2018. The mean age of cases was 30 years, 79% worked in a healthcare setting and 87% were vaccinated. Genotype B3 was identified in 84 cases from the three outbreaks. Primary cases in each outbreak were imported. Several cases presented with modified measles, highlighting the importance of rethinking the measles case definition for vaccinated cases.

We present preliminary findings and implemented control measures of three simultaneous measles outbreaks that occurred in Portugal between February and April 2018. One of the outbreaks took place in a hospital and represented a particular challenge for epidemiological and laboratory investigations as a substantial number of vaccinated healthcare workers (HCWs) developed benign clinical signs and symptoms of measles. We discuss these findings and highlight the need to expand the European Union (EU) measles case definition, in order to increase sensitivity in case capture among vaccinated individuals with modified measles and who do not meet the current European Union (EU) case definition.

Case definition
Measles case definition used for epidemiological surveillance in Portugal is based on the EU case definition [1]. A possible case is any person who meets clinical criteria (i.e. fever, maculopapular rash, and any of cough/coryza/conjunctivitis); a probable case is any person who meets clinical criteria and has an epidemiological link to a confirmed case; a confirmed case is any possible case with laboratory evidence of infection with measles wild virus (i.e. detection of viral RNA in a biological sample and/or a positive IgM result in serum), determined by the World Health Organization (WHO)-certified national reference laboratory for measles and rubella National Institute of Health – Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon [2]. Cases are discarded when clinical, epidemiological or laboratory criteria are not met, taking into account vaccination history and risk of measles infection in the community or abroad, following WHO criteria [3].

However, symptoms in modified measles cases are masked meaning that cases do not present with the usual signs and symptoms of classic measles, this making a clinical diagnosis more challenging. Modified measles mainly affects young adults who have been vaccinated, suggesting that they could have suboptimal protection against measles whether it be from insufficient number of vaccination doses or that the immunity to disease has waned over time as revealed in the National Serological Survey (2015/2016) [4]. Therefore, the case definition used during this outbreak was expanded to increase sensitivity: clinical criteria included any person with a maculopapular rash, or fever or any of the following three symptoms: cough, coryza, conjunctivitis. Epidemiological criteria included any person with a link to the hospital or with a confirmed measles case.

Outbreak description
On 9 March 2018, a laboratory-confirmed measles case was notified by INSA. It corresponded to an unvaccinated French citizen, recently arrived in the North
Health region from the Aquitaine Region, where a measles outbreak has been ongoing [5]. Following the laboratory notification, the case was clinically notified on 12 March in the National System for Epidemiological Surveillance (Sistema Nacional de Vigilância Epidemiológica, SINAVE), which is an integrated clinical and laboratory electronic system of mandatory notification. This case was the source of infection for three additional cases in close relatives that either lived with or visited the case; all had been vaccinated with two measles-mumps-rubella (MMR) doses. No further cases were related to this chain of transmission.

On 13 March 2018, the clinical director of a hospital in Oporto reported 24 suspected measles cases among the hospital’s HCWs to public health authorities. All suspected cases had a link with the Emergency Department and presented with maculopapular rash, tachycardia, low fever and headache. The following day, INSA confirmed the first two cases along with a third, who had not been vaccinated and had developed a rash. Overall, there were 103 confirmed measles cases associated with this primary case. Most cases were HCWs (n = 87; 84.5%), of which 10 (11.5%) were vaccinated with one dose of a measles-containing vaccine, 66 (75.9%) with two doses, four (4.6%) with three doses, and seven (8.0%) were unvaccinated.

On 26 and 28 March, two cases with history of recent travel to two different African countries and both having a stopover at the same airport on the same day during the incubation period (and evidence of remaining in the same waiting room) were notified in SINAVE. One of the cases was vaccinated with two MMR doses and did not infect further cases. The other case was unvaccinated and infected three additional cases, one at work and two contacts in a hospital Emergency Department. From 12 March until 31 May, a total of 440 suspected measles cases were notified in SINAVE, of which 112 (25.5%) were laboratory-confirmed in INSA, 303 (68.9%) were discarded and 25 (5.7%) were still under investigation. Figure 1 shows the distribution of all confirmed measles cases by date of symptom onset and chain of transmission. Overall, 47 (45.6%) cases in this chain of transmission had benign clinical signs and symptoms of measles. History of vaccination was verified from individuals’ medical charts or from the national immunisation registry.

Of the 112 confirmed measles cases the mean age was 30 years (SD: 7.7) and 65 cases were female. Preliminary findings show that 111 confirmed measles
|                                      | France-related chain of transmission | Italy-related chain of transmission | Africa-related chain of transmission | Total | n  | %  |
|--------------------------------------|--------------------------------------|-------------------------------------|-------------------------------------|-------|----|----|
| Total                                | 4                                    | 103                                 | 5                                   | 112   | 100.0 |
| Sex                                  |                                      |                                     |                                     |       |     |    |
| Female                               | 2                                    | 62                                  | 1                                   | 65    | 58.0 |
| Male                                 | 2                                    | 41                                  | 4                                   | 47    | 42.0 |
| Age group (years)                    |                                      |                                     |                                     |       |     |    |
| < 1                                  | 0                                    | 0                                   | 0                                   | 0     | 0.0 |
| 1–9                                  | 0                                    | 1                                   | 0                                   | 1     | 0.9 |
| 10–19                                | 0                                    | 0                                   | 0                                   | 0     | 0.0 |
| 20–29                                | 2                                    | 52                                  | 1                                   | 55    | 49.1 |
| 30–39                                | 2                                    | 40                                  | 3                                   | 45    | 40.2 |
| 40–49                                | 0                                    | 8                                   | 1                                   | 9     | 8.0 |
| 50–59                                | 0                                    | 2                                   | 0                                   | 2     | 1.8 |
| ≥ 60                                 | 0                                    | 0                                   | 0                                   | 0     | 0.0 |
| Vaccination status                   |                                      |                                     |                                     |       |     |    |
| Not vaccinated                       | 1                                    | 13                                  | 1                                   | 15    | 13.4 |
| 1 dose                               | 0                                    | 12                                  | 2                                   | 14    | 12.5 |
| 2 doses                              | 3                                    | 74                                  | 2                                   | 79    | 70.5 |
| 3 doses                              | 0                                    | 4                                   | 0                                   | 4     | 3.6 |
| Occupation                           |                                      |                                     |                                     |       |     |    |
| Non-Healthcare workers               | 3                                    | 16                                  | 4                                   | 23    | 20.5 |
| Doctors                              | 1                                    | 33                                  | 0                                   | 34    | 30.4 |
| Nurses                               | 0                                    | 20                                  | 0                                   | 20    | 17.9 |
| Allied professionals                 | 0                                    | 15                                  | 1                                   | 16    | 14.3 |
| Medical/Nursing students             | 0                                    | 18                                  | 0                                   | 18    | 16.0 |
| Other Healthcare workers             | 0                                    | 1                                   | 0                                   | 1     | 0.9 |
| Measles symptoms                     |                                      |                                     |                                     |       |     |    |
| Maculopapular rash + Fever + Cough/Coryza/Conjunctivitis | 1 | 56 | 5 | 62 | 55.4 |
| Maculopapular rash only              | 2                                    | 11                                  | 0                                   | 13    | 11.6 |
| Fever only                           | 0                                    | 2                                   | 0                                   | 2     | 1.8 |
| Maculopapular rash + Fever           | 1                                    | 23                                  | 0                                   | 24    | 21.4 |
| Maculopapular rash + Cough           | 0                                    | 1                                   | 0                                   | 1     | 0.9 |
| Maculopapular rash + Coryza          | 0                                    | 7                                   | 0                                   | 7     | 6.2 |
| Fever + Coryza                       | 0                                    | 1                                   | 0                                   | 1     | 0.9 |
| Fever + Cough + Coryza               | 0                                    | 1                                   | 0                                   | 1     | 0.9 |
| Cough + Coryza                       | 0                                    | 1                                   | 0                                   | 1     | 0.9 |
| Laboratory results                   |                                      |                                     |                                     |       |     |    |
| Detection of viral RNA               | 3                                    | 80                                  | 5                                   | 88    | 78.6 |
| Positive IgM                         | 0                                    | 3                                   | 0                                   | 3     | 2.7 |
| Increase of both IgM and IgG in a pair of samples | 1 | 7 | 0 | 8 | 7.1 |
| Increase of IgM in a pair of samples | 0 | 3 | 0 | 3 | 2.7 |
| Increase of IgG in a pair of samples | 0 | 10 | 0 | 10 | 8.9 |
| Genotype                             | B3                                    | 2                                   | 78                                  | 4     | 84   | 64.1 |

Source: Direção-Geral da Saúde, Sistema Nacional de Vigilância Epidemiológica, Instituto Nacional de Saúde Dr Ricardo Jorge.
cases occurred in adults (≥ 18 years), with an age range of 20–54 years and one case in a 3-year-old child vaccinated with one MMR dose (Table 1). Among the 112 confirmed cases, 83 (74.1%) were vaccinated with two or more doses of a measles-containing vaccine. Fifty (44.6%) confirmed cases did not meet the clinical criteria from the EU case definition; among them, 24 of 50 had a maculopapular rash and fever as clinical presentation and 13 cases (11.6%) only had a maculopapular rash. Twenty-one cases (18.8%) were confirmed through laboratory results of second samples, where an increase of either IgM, IgG or both was verified (Table 1). Among the 88 cases where viral RNA was detected, 84 cases could be genotyped. Genotype B3 was identified in cases from all the three chains of transmission, although the four cases from the Africa-related chain of transmission had a 5 nucleotide difference from the genotype B3 identified in the other two chains of transmission, which was phylogenetically indistinct.

The measles outbreaks affected three of the seven Portuguese Health Regions (Figure 2), with the majority of cases 107 of 112 (95.5%) reported in the North Health Region.

Control measures
Following the laboratory notification of the first confirmed measles case, DGS issued a warning to healthcare services that was followed by recommendations and guidelines regarding diagnosis, early detection and response to measles cases, within the scope of the National Measles Elimination Programme [6].

In order to control the outbreak on a local level and mitigate transmission outside the healthcare setting, an Emergency Response Team comprising of hospital and public health professionals was created in the affected hospital in Oporto [7]. A vaccination point within the hospital was set-up allowing for rapid vaccination of close contacts and unvaccinated individuals.

During the outbreaks, all suspected measles cases reported were investigated and control measures were promptly implemented to contain further transmission. Local public health teams undertook extensive contact tracing for all suspected measles cases. Surveillance and control measures included immediate isolation of suspected cases, verification of immunisation status of close contacts and administration of prophylactic immunoglobulin or MMR vaccine, whenever necessary. In addition, control measures were complemented with broader public health measures, including the dissemination of key documents to support prevention and control measures [8,9] and raising public awareness about the importance of vaccination through numerous reports in the national media as well as a large media campaign. Daily press releases and epidemiological bulletins were issued by DGS while the outbreaks lasted.
As the primary or index cases did not originate in Portugal or had stayed in another country during their incubation period, the director-general of Health in Portugal notified the Health Authorities from these countries regarding the cases, following the International Health Regulations [10].

Discussion
Following 12 years without endemic measles transmission, Portugal experienced two measles outbreaks in 2017 [11] and, so far, three measles outbreaks in 2018. In two of these transmission mainly occurred in the community setting, whereas one mainly occurred in a healthcare setting. The high coverage of measles vaccination and the timely implementation of control measures allowed for the rapid containment of measles and interruption of all chains of transmission. The outbreaks were declared over on 10 June 2018 and since 29 April 2018 no new cases have been detected [12]. The immediate isolation of cases, extensive contact tracing and vaccination were crucial to contain the outbreak in the Oporto hospital and avoid its spread to the community.

Vaccination or acquired immunity after illness constitute adequate protection against measles [13]. Since the measles vaccine was introduced in the Portuguese National Immunisation Programme in 1974, the country has achieved a consistent and sustained high immunisation coverage against measles (> 95%) [11,14].

HCWs are at higher risk of measles exposure because the high intensity of the exposure and subsequent transmission to vulnerable patients [15]. According to the National Measles Elimination Programme, HCWs are recommended to receive two doses of measles vaccine (either single measles-containing vaccine or MMR) or to have evidence of previous measles infection [6]. However, measles outbreaks in healthcare settings are becoming more frequent in the European Region [15-18]. Countries, such as Portugal, which maintained a high vaccination coverage for many years and had eliminated measles, are at greater risk of modified measles cases emerging during outbreaks. This is due to suboptimal protection against measles, either from insufficient number of vaccine doses or waning immunity from the vaccine over time (as indicated by the National Serological Survey 2015/2016). Modified measles mainly affect young adults who were adequately vaccinated but with the last dose of the vaccine administered more than 10 years prior.

In one chain of transmission, a hospital cluster was identified and most cases were HCWs vaccinated with two or more doses of MMR vaccine. This was described in other outbreaks [18] and may be related to waning of vaccine-induced immunity in the absence of natural boosting by the wildtype virus [19].

Modified measles cases has been described in vaccinated individuals [20,21]. In the outbreaks reported here, this was the case in 50 of 112 (44.6%) confirmed cases. Early findings of modified measles led us to expand the case definition initially in place in order to increase sensitivity. Interestingly, 5 of 112 (4.5%) confirmed cases did not have a maculopapular rash, and their symptoms would have been easily mistaken for other clinical conditions if they were not investigated in the context of a measles outbreak. Also, laboratory confirmation was only possible due to the collection of second serum samples in 21 of 112 cases, where an increase of IgM or IgG antibodies was verified [22].

The outbreaks described here, which included a number of cases with modified measles and a large number of cases among vaccinated HCWs, highlight the need for further investigation in order to recommend innovative approaches in future outbreaks: Nearly half of these cases would not have been identified using the current EU case definition. Thus, in light of these new findings and in order to increase sensitivity in case capture in the context of an outbreak, it would be important to develop an additional case classification suited for a community with high vaccination coverage with epidemiological criteria, that may lead to the definition of risk levels for public health intervention according to the type of exposure or depending to exposure to cases of reinfection.

Acknowledgements
The authors wish to thank all members of local public health units, regional public health departments and the Directorate-General of Health who participated in investigations and control measures in these outbreaks. The authors also wish to thank to all members in the National Institute of Health Dr Ricardo Jorge who were involved in the laboratory investigation and genotypic analysis of measles cases. Special thanks go also to all doctors, nurses and other healthcare workers in hospitals and primary care units who have assisted with control measures, as well as all patients and their families who promptly cooperated in the epidemiological investigations.

Conflict of interest
None declared.

Authors’ contributions
GF, DC, AS and PN coordinated the investigations of the outbreak at the national level. MN coordinated the investigation at the regional level in the North Region. GFA, BA, NP, ES, TF, PV and AL contributed to data collection, case information and data analysis. PP, EV, SL, RC and ESL were involved in the laboratory investigations. GFA drafted the manuscript, with contributions by NP, BA, AL and PP. All authors were involved in revising the manuscript. All authors reviewed and approved the final version.

References
1. European Commission. Commission Implementing Decision of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases
to the Community network under Decision No 2199/98/EC of the European Parliament and of the Council. Luxembourg: Publications Office of the European Union. L262 Sep 27, 2012. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=0%3A%2A2012%2A262%3ATOC

2. Republic of Portugal. Despacho N.° 15385-A/2016 [Dispatch No. 15385-A/2016], in Diário da República (Government Gazette), Serie II, 21 December 2016, [Portuguese]. Available from: https://dre.pt/home/-/diretor/10557433/details/maximized?serie=11&red=10557433

3. World Health Organization (WHO). Eliminating Measles and rubella - Framework for the verification process in the WHO European Region 2014, Copenhagen: WHO; 2014. Available from: http://www.euro.who.int/__data/assets/pdf_file/0009/247356/eliminating-measles-and-rubella-framework-for-the-verification-process-in-the-WHO-European-Region.pdf

4. National Institute of Health Dr Ricardo Jorge (INSA). Inquérito Serológlico Nacional 2015-16 [National Serological Survey 2015-16], Lisbon: INSA; 2017. Available from: http://repository.insa.pt/handle/10400.18/5401

5. French Public Health Agency. Rougeole: Bulletin épidémiologique Semaine 19, 16/05/2018 [Measles: Epidemiological Bulletin Week 19, 16/05/2018], Paris: Public Health Agency; 2018. [French]: available from: http://invs.sante publiquefrance.fr/content/download/146828/534556/version/18/file/Bulletin_rougeole_519.pdf

6. Directorate-General of Health (DGS), Programa Nacional para a Eliminação do Sarampo [National Measles Elimination Programme], Lisbon: DGS; March 2013. Available from: https://www.dgs.pt/documentos-e-publicacoes/programa-nacional-de-eliminacao-do-sarampo-jpg.aspx

7. Sá Machado R, Perez Duque M, Almeida S, Cruz I, Sottomayor A, Almeida I, et al. Measles outbreak in a tertiary level hospital, Porto, Portugal, 2018: challenges in the post-elimination era. Euro Surveill. 2018;23(20):18-00224. https://doi.org/10.2807/1560-7917.ES.2018.23.20.18-00224 PMID: 29790461

8. Directorate-General of Health (DGS), Sarampo – Procedimentos em unidades de saúde – Programa Nacional Eliminação de Sarampo [Measles – Procedures in Healthcare Units – National Measles elimination Programme, Informations to Schools], Lisbon: DGS; March 2018. Normative Document No. 004/2017 updated on 16 March 2018. [Portuguese]. Available from: https://www.dgs.pt/paginas-de-sistema/saude-de-a-a-z/sarampo1/normas-e-orientacoes.aspx

9. Directorate-General of Health (DGS). Sarampo: Controlo de Infeção em unidades de saúde [Measles: Infection Control in Healthcare Units], Lisbon: DGS; March 2018. Guideline No. 001/2018. [Portuguese]. Available from: https://www.dgs.pt/paginas-de-sistema/saude-de-a-a-z/sarampo1/normas-e-orientacoes.aspx

10. World Health Organization (WHO), International Health Regulations (2005) 3rd ed. Geneva: WHO; 2005. Available from: http://www.who.int/ihr/publications/9789241566664/en/

11. George F, Valente J, Augusto GF, Pereira N, Fernandes T, et al. Measles outbreak after 12 years without endemic transmission, Portugal, February to May 2017. Euro Surveill. 2017;22(3):19280. https://doi.org/10.2807/1560-7917.ES.2017.22.23.19280 PMID: 28840825

12. Directorate-General of Health (DGS), Boletim do Programa Nacional de Vacinação [National Immunisation Programme Bulletin], Lisbon: DGS; May 2018. [Portuguese]. Available from: https://www.dgs.pt/documentos-e-publicacoes/avaliacao-do-programa-nacional-de-vacinacao-2017-pdf.aspx

13. Christenson B, Böttiger M. Measles antibodies: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine. 1994;12(3):29-33. https://doi.org/10.1016/0264-410X(94)90049-3 PMID: 8147973

14. Directorate-General of Health (DGS), Directorate-General of Health (DGS), Boletim do Programa Nacional de Vacinação [National Immunisation Programme Bulletin], Lisbon: DGS; May 2018. [Portuguese]. Available from: https://www.dgs.pt/documentos-e-publicacoes/avaliacao-do-programa-nacional-de-vacinacao-2017-pdf.aspx

15. Porretta A, Quattroone F, Aquino F, Pieve G, Bruni B, Gemignani G, et al. A nosocomial measles outbreak in Italy, February-April 2017. Euro Surveill. 2017;22(3):30597. https://doi.org/10.2807/1560-7917.ES.2017.22.23.30597 PMID: 28480827

16. Komitova R, Kunchev A, Mihneva Z, Marinova L. Nosocomial transmission of measles among healthcare workers, Bulgaria, 2010. Euro Surveill. 2011;16(35):19842. https://doi.org/10.2807/esr.16.35.19842-en PMID: 21507322

17. Amendola A, Bianchi S, Frati ER, Ciceri G, Faccini M, Senatore S, et al. Ongoing large measles outbreak with nosocomial transmission in Milan, northern Italy, March-August 2017, Euro Surveill. 2017;22(33):30596. https://doi.org/10.2807/1560-7917.ES.2017.22.33.30596 PMID: 28840825

18. Hahné SJ, Nic Lochlainn LM, van Burgel ND, Kerkhof J, Sane J, Yap KB, et al. Measles Outbreak Among Previously Immunized Healthcare Workers, the Netherlands, 2014. J Infect Dis. 2016;214(2):398-6. https://doi.org/10.1093/infdis/jiw480 PMID: 27923955

19. Kang HJ, Han YW, Kim SJ, Kim YJ, Kim AR, Kim JA, et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine. 2017;35(33):4126-32. https://doi.org/10.1016/j.vaccine.2017.06.058 PMID: 28669617

20. Rota JS, Hickman CJ, Sowers SB, Rota PA, Mercader S, Bellini WJ. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. J Infect Dis. 2011;204(Suppl 1):S559-65. https://doi.org/10.1093/infdis/jir098 PMID: 21666213

21. Lee NY, Lee HC, Chang CM, Wu CJ, Ko NY, Ko WC. Modified measles in a healthcare worker after return from travel. Infect Control Hosp Epidemiol. 2008;29(4):380-1. https://doi.org/10.1086/529031 PMID: 18626155

22. World Health Organization (WHO). Manual for the laboratory diagnosis of measles and rubella virus infection. (2nd Ed). Geneva: WHO; 2007. Available from: http://www.who.int/ihr/elibRARY/manual_dIAGN_diag_NAme_ruB_enpdf

License and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors or their affiliated institutions, 2018.